[1]
|
Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E. and Forman, D. (2011) Global cancer statistics. CA: A Cancer Journal for Clinicians, 61, 69-90. http://dx.doi.org/10.3322/caac.20107
|
[2]
|
Siegel, R., DeSantis, C., Virgo, K., Stein, K., Mariotto, A., Smith, T., Cooper, D., Gansler, T., Lerro, C., Fedewa, S., Lin, C., Leach C, Cannady, R.S., Cho, H., Scoppa, S., Hachey, M., Kirch, R., Jemal, A. and Ward, E. (2012) Cancer treatment and survivorship statistics. CA: A Cancer Journal for Clinicians, 62, 220-241. http://dx.doi.org/10.3322/caac.21149
|
[3]
|
Ferguson, N.L., Bell, J., Heidel, R., Lee, S., Vanmete, S, Duncan, L., Munsey, B., Panella, T. and Orucevic, A. (2013) Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women. Breast Journal, 19, 22-30. http://dx.doi.org/10.1111/tbj.12059
|
[4]
|
Buijs, J.T. and Pluijm, G. (2009) Osteotropic cancers: From primary tumor to bone. Cancer Letters, 273, 177-193. http://dx.doi.org/10.1016/j.canlet.2008.05.044
|
[5]
|
Coleman, R.E. (1997) Skeletal complications of malignancy. Cancer, 80, 1588-1594.
|
[6]
|
Mundy, G.R. (2002) Metastasis to bone: Causes, consequences and therapeutic opportunities. Nature Reviews Cancer, 2, 584-593. http://dx.doi.org/10.1038/nrc867
|
[7]
|
Oster, G., Lamerato, L., Glass, A.G., Richert-Boe, K.E., Lopez, A., Chung, K., Richhariya, A., Dodge, T., Wolff, G.G., Balakumaran, A. and Edelsberg, J. (2013) Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer.
|
[8]
|
Roodman, G.D. (2004) Mechanisms of bone metastasis. The New England Journal of Medicine, 350, 1655-1664. http://dx.doi.org/10.1056/NEJMra030831
|
[9]
|
Korpal, M., Yan, J., Lu, X., Xu, S., Lerit, D.A. and Kang, Y. (2009) Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nature Medicine, 15, 960-966. http://dx.doi.org/10.1038/nm.1943
|
[10]
|
Kang, Y., Siegel, P.M., Shu, W., Drobnjak, M., Kakonen, S.M., Cordon-Cardo, C., Guise, T.A. and Massague, J. (2003) A multigenic program mediating breast cancer metastasis to bone. Cancan Cell, 3, 537-549. http://dx.doi.org/10.1016/S1535-6108(03)00132-6
|
[11]
|
Yin, J.J., Selander, K., Chirgwin, J.M., Dallas, M., Grubbs, B.G., Wieser, R., Massague, J., Mundy, G.R. and Guise, T.A. (1999) TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. Journal of Clinical Investigationing, 103, 197-206. http://dx.doi.org/10.1172/JCI3523
|
[12]
|
Yingling, J.M., Blanchard, K.L. and Sawyer, J.S. (2004) Development of TGF-beta signalling inhibitors for cancer therapy. Nature Reviews Drug Discovery, 3, 1011-1022. http://dx.doi.org/10.1038/nrd1580
|
[13]
|
Massague, J., Blain, S.W. and Lo, R.S. (2000) TGF beta signaling in growth control, cancer, and heritable disorders. Cell, 103, 295-309. http://dx.doi.org/10.1016/S0092-8674(00)00121-5
|
[14]
|
Blobe, G.C., Schiemann, W.P. and Lodish, H.F. (2000) Role of transforming growth factor beta in human disease. The New England Journal of Medicine, 342, 1350-1358. http://dx.doi.org/10.1056/NEJM200005043421807
|
[15]
|
Dijke, P. and Arthur, H.M. (2007) Extracellular control of TGFbeta signalling in vascular development and disease. Nature Reviews Molecular Cell Biology, 8, 857-869. http://dx.doi.org/10.1038/nrm2262
|
[16]
|
Massague, J. (2000) How cells read TGF-beta signals. Nature Reviews Molecular Cell Biology, 1, 169-178. http://dx.doi.org/10.1038/35043051
|
[17]
|
Feng, X.H. and Derynck, R. (2005) Specificity and versatility in tgf-beta signaling through Smads. Annual Review of Cell and Developmental Biology, 21, 659-693. http://dx.doi.org/10.1146/annurev.cellbio.21.022404.142018
|
[18]
|
Shi, Y. and Massague, J. (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell, 113, 685-700. http://dx.doi.org/10.1016/S0092-8674(03)00432-X
|
[19]
|
Wu, M.Y. and Hill, C.S. (2009) Tgf-beta superfamily signaling in embryonic development and homeostasis. Developmental Cell, 16, 329-343. http://dx.doi.org/10.1016/j.devcel.2009.02.012
|
[20]
|
Derynck, R. and Zhang, Y.E. (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature, 425, 577-584. http://dx.doi.org/10.1038/nature02006
|
[21]
|
Hinck, A.P. (2012) Structural studies of the TGF-bs and their receptors—Insights into evolution of the TGF-b superfamily. FEBS Letters, 586, 1860-1870. http://dx.doi.org/10.1016/j.febslet.2012.05.028
|
[22]
|
Ikushima, H., Komuro, A., Isogaya, K., Shinozaki, M., Hellman, U., Miyazawa, K. and Miyazono, K. (2008) An Id-like molecule, HHM, is a synexpression group-restricted regulator of TGF-beta signalling. EMBO Journal, 27, 2955-2965. http://dx.doi.org/10.1038/emboj.2008.218
|
[23]
|
Ikushima, H. and Miyazono, K. (2010) TGF beta signalling: A complex web in cancer progression. Nature Reviews Cancer, 10, 415-424. http://dx.doi.org/10.1038/nrc2853
|
[24]
|
Wakefield, L.M. and Hill, C.S. (2013) Beyond TGFβ: Roles of other TGFβ superfamily members in cancer. Nature Reviews Cancer, 13, 328-341. http://dx.doi.org/10.1038/nrc3500
|
[25]
|
Daly, A.C., Randall, R.A. and Hill, C.S. (2008) Transforming growth factor beta-induced Smad1/5 phosphorylation in epithelial cells is mediated by novel receptor complexes and is essential for anchorage-independent growth. Molecular and Cellular Biology, 28, 6889-6902. http://dx.doi.org/10.1128/MCB.01192-08
|
[26]
|
Liu, I.M., Schilling, S.H., Knouse, K.A., Choy, L., Derynck, R. and Wang, X.F. (2009) TGF beta-stimulated Smad1/5 phosphorylation requires the ALK5 L45 loop and mediates the pro-migratory TGFbeta switch. EMBO Journal, 28, 88-98. http://dx.doi.org/10.1038/emboj.2008.266
|
[27]
|
Pardali, E., Goumans, M.J. and Dijke, P. (2010) Signaling by members of the TGF-beta family in vascular morphogenesis and disease. Trends in Cell Biology, 20, 556-567. http://dx.doi.org/10.1016/j.tcb.2010.06.006
|
[28]
|
Goumans, M.J., Valdimarsdottir, G., Itoh, S., Lebrin, F., Larsson, J., Mummery, C., Karlsson, S. and Dijke, P. (2003) Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Molecular Cell, 12, 817-828. http://dx.doi.org/10.1016/S1097-2765(03)00386-1
|
[29]
|
Goumans, M.J., Valdimarsdottir, G., Itoh, S., Rosendahl, A., Sideras, P. and Dijke, P. (2002) Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO Journal, 21, 1743-1753. http://dx.doi.org/10.1093/emboj/21.7.1743
|
[30]
|
Kang, J.S., Liu, C. and Derynck, R. (2009) New regulatory mechanisms of TGF-beta receptor function. Trends in Cell Biology, 19, 385-394. http://dx.doi.org/10.1016/j.tcb.2009.05.008
|
[31]
|
Lee, M.K., Pardoux, C., Hall, M.C., Lee, P.S., Warburton, D., Qing, J., Smith, S.M. and Derynck, R. (2007) TGFbeta activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO Journal, 26, 3957-3967. http://dx.doi.org/10.1038/sj.emboj.7601818
|
[32]
|
Sorrentino, A., Thakur, N., Grimsby, S., Marcusson, A., von Bulow, V., Schuster, N., Zhang, S., Heldin, C.H. and Landstrom, M. (2008) The type I TGF-beta receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner. Nature Cell Biology, 10, 1199-1207. http://dx.doi.org/10.1038/ncb1780
|
[33]
|
Yamashita, M., Fatyol, K., Jin, C., Wang, X., Liu, Z. and Zhang, Y.E. (2008) TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-beta. Molecular Cell, 31, 918-924. http://dx.doi.org/10.1016/j.molcel.2008.09.002
|
[34]
|
Vergara, D., Merlot, B., Lucot, J.P., Collinet, P., Vinatier, D., Fournier, I. and Salzet, M. (2010) Epithelial-mesenchymal transition in ovarian cancer. Cancer Letter, 291, 59-66. http://dx.doi.org/10.1016/j.canlet.2009.09.017
|
[35]
|
Xu, J., Lamouille, S. and Derynck, R. (2009) TGF-β-induced epithelial to mesenchymal transition. Cell Research, 19, 156-172. http://dx.doi.org/10.1038/cr.2009.5
|
[36]
|
Moustakas, A. and Heldin, C.H. (2007) Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Science, 98, 1512-1520. http://dx.http://dx.doi.org/10.1111/j.1349-7006.2007.00550.x
|
[37]
|
Vincent, T., Neve, E.P., Johnson, J.R., Kukalev, A., Rojo, F., Albanell, J., Pietras, K., Virtanen, I., Philipson, L., Leopold, P.L., Crystal, R.G., de Herreros, A.G., Moustakas, A., Pettersson, R.F. and Fuxe, J. (2009) A SNAIL1SMAD3/4 transcriptional repressor complex promotes TGF-b mediated epithelial-mesenchymal transition. Nature Cell Biology, 11, 943-950. http://dx.http://dx.doi.org/10.1038/ncb1905
|
[38]
|
Bracken, C.P., Gregory, P.A., Kolesnikoff, N., Bert, A.G., Wang, J., Shannon, M.F. and Goodall, G.J. (2008) A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Research, 68, 7846-7854. http://dx.http://dx.doi.org/10.1158/0008-5472.CAN-08-1942
|
[39]
|
Moustakas, A. and Heldin, C.H. (2012) Induction of epithelial-mesenchymal transition by transforming growth factor beta. Seminars in Cancer Biology, 22, 446-454. http://dx.http://dx.doi.org/10.1016/j.semcancer.2012.04.002
|
[40]
|
Horiguchi, K., Sakamoto, K., Koinuma, D., Semba, K., Inoue, A., Inoue, S., Fujii, H., Yamaguchi, A., Miyazawa, K., Miyazono, K. and Saitoh, M. (2012) TGF-β drives epithelial-mesenchymal transition through deltaEF1-mediated downregulation of ESRP. Oncogene, 31, 3190-3201. http://dx.http://dx.doi.org/10.1038/onc.2011.493
|
[41]
|
Ozdamar, B., Bose, R., Barrios-Rodiles, M., Wang, H.R., Zhang, Y. and Wrana, J.L. (2005) Regulation of the polarity protein Par6 by TGFβ receptors controls epithelial cell plasticity. Science, 307, 1603-1609. http://dx.http://dx.doi.org/10.1126/science.1105718
|
[42]
|
Katsuno, Y., Lamouille, S. and Derynck, R. (2013) TGF-β signaling and epithelial-mesenchymal transition in cancer progression. Current Opinion in Oncology, 25, 76-84. http://dx.http://dx.doi.org/10.1097/CCO.0b013e32835b6371
|
[43]
|
Netherton, S.J. and Bonni, S. (2010) Suppression of TGFβ-induced epithelial-mesenchymal transition like phenotype by a PIAS1 regulated sumoylation pathway in NMuMG epithelial cells. PLoS ONE, 5, e13971. http://dx.http://dx.doi.org/10.1371/journal.pone.0013971
|
[44]
|
Derynck, R. and Akhurst, R.J. (2007) Differentiation plasticity regulated by TGF-beta family proteins in development and disease. Nature Cell Biology, 9, 1000-1004. http://dx.http://dx.doi.org/10.1038/ncb434
|
[45]
|
Massague, J. and Chen, Y.G. (2000) Controlling TGFbeta signaling. Genes & Development, 14, 627-644.
|
[46]
|
Massague, J. (2008) TGFbeta in Cancer. Cell, 134, 215-230. http://dx.http://dx.doi.org/10.1016/j.cell.2008.07.001
|
[47]
|
Thiery, J.P., Acloque, H., Huang, R.Y. and Nieto, M.A. (2009) Epithelial-mesenchymal transitions in development and disease. Cell, 139, 871-890. http://dx.http://dx.doi.org/10.1016/j.cell.2009.11.007
|
[48]
|
Yang, Y.A., Dukhanina, O., Tang, B., Mamura, M., Letterio, J.J., MacGregor, J., Patel, S.C., Khozin, S., Liu, Z.Y., Green, J., Anver, M.R., Merlino, G. and Wakefield, L.M. (2002) Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. Journal of Clinical Investigation, 109, 1607-1615.
|
[49]
|
Gorska, A.E., Jensen, R.A., Shyr, Y., Aakre, M.E., Bhowmick, N.A. and Moses, H.L. (2003) Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-beta receptor exhibit impaired mammary development and enhanced mammary tumor formation. American Journal of Pathology, 63, 1539-1549. http://dx.http://dx.doi.org/10.1016/S0002-9440(10)63510-9
|
[50]
|
Lenferink, A.E., Magoon, J., Pepin, M.C., Guimond, A. and O’Connor-McCourt, M.D. (2003) Expression of TGF-beta type II receptor antisense RNA impairs TGFbeta signaling in vitro and promotes mammary gland differentiation in vivo. International Journal of Cancer, 107, 919-928. http://dx.http://dx.doi.org/10.1002/ijc.11494
|
[51]
|
Muraoka, R.S., Koh, Y., Roebuck, L.R., Sanders, M.E., Brantley-Sieders, D., Gorska, A.E., Moses, H.L. and Arteaga, C.L. (2003) Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1. Molecular and Cellular Biology, 23, 8691-8703. http://dx.http://dx.doi.org/10.1128/MCB.23.23.8691-8703.2003
|
[52]
|
Siegel, P.M., Shu, W., Cardiff, R.D., Muller, W.J. and Massague, J. (2003) Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proceedings of the National Academy of Sciences of the United States of America, 100, 8430-8435. http://dx.http://dx.doi.org/10.1073/pnas.0932636100
|
[53]
|
Zakharchenko, O., Cojoc, M., Dubrovska, A. and Souchelnytskyi, S. (2013) A role of TGFβ1 dependent 14-3-3σ phosphorylation at Ser69 and Ser74 in the regulation of gene transcription, stemness and radioresistance. PLoS ONE, 8, e65163. http://dx.http://dx.doi.org/10.1371/journal.pone.0065163
|
[54]
|
Wang, Y. and Lui, W.Y. (2012) Transforming growth factor-β1 attenuates junctional adhesion molecule-A and contributes to breast cancer cell invasion. European Journal of Cancer, 48, 3475-3487. http://dx.http://dx.doi.org/10.1016/j.ejca.2012.04.016
|
[55]
|
Johansson, J., Berg, T., Kurzejamska, E., Pan, M.F., Tabor, V., Jansson, M., Roswall, P., Pietras, K., Sund, M., Religa, P. and Fuxe. J. (2013) MiR-155-mediated loss of C/EBPβ shifts the TGF-β response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer. Oncogene.
|
[56]
|
Forrester, E., Chytil, A., Bierie, B., Aakre, M., Gorska, A.E., Sharif-Afshar, A.R., Muller, W.J. and Moses, H.L. (2005) Effect of conditional knockout of the type II TGFbeta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Research, 65, 2296-2302. http://dx.http://dx.doi.org/10.1158/0008-5472.CAN-04-3272
|
[57]
|
Muraoka-Cook, R.S., Shin, I., Yi, J.Y., Easterly, E., Barcellos-Hoff, M.H., Yingling, J.M., Zent, R. and Arteaga, C.L. (2006) Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. Oncogene, 25, 3408-3423. http://dx.http://dx.doi.org/10.1038/sj.onc.1208964
|
[58]
|
Gorsch, S.M., Memoli, V.A., Stukel, T.A., Gold, L.I. and Arrick, B.A. (1992) Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Research, 52, 6949-6952.
|
[59]
|
Tan, A.R., Alexe, G. and Reiss, M. (2009) Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer? Breast Cancer Research and Treatment, 115, 453-495. http://dx.http://dx.doi.org/10.1007/s10549-008-0184-1
|
[60]
|
Travers, M.T., Barrett-Lee, P.J., Berger, U., Luqmani, Y.A., Gazet, J.C., Powles, T.J. and Coombes RC. (1988) Growth factor expression in normal, benign, and malignant breast tissue. British Medical Journal, 296, 1621-1624. http://dx.http://dx.doi.org/10.1136/bmj.296.6637.1621
|
[61]
|
Jong, J.S., Diest, P.J., Valk, P. and Baak, J.P. (1998) Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis. The Journal of Pathology, 184, 53-57. http://dx.http://dx.doi.org/10.1002/(SICI)1096-9896(199801)184:1<53::AID-PATH6>3.0.CO;2-7
|
[62]
|
Grau, A.M., Wen, W., Ramroopsingh, D.S., Gao, Y.T., Zi, J., Cai, Q., Shu, X.O. and Zheng, W. (2008) Circulating transforming growth factor-beta-1 and breast cancer prognosis: results from the Shanghai Breast Cancer Study. Breast Cancer Research and Treatment, 112, 335-341. http://dx.http://dx.doi.org/10.1007/s10549-007-9845-8
|
[63]
|
Ivanovic, V., Todorovic-Rakovic, N., Demajo, M., Neskovic-Konstantinovic, Z., Subota, V., Ivanisevic-Milovanovic, O. and Nikolic-Vukosavljevic, D. (2003) Elevated plasma levels of transforming growth factor-beta 1 (TGF-beta 1) in patients with advanced breast cancer: association with disease progression. European Journal of Cancer, 39, 454-461. http://dx.http://dx.doi.org/10.1016/S0959-8049(02)00502-6
|
[64]
|
Kong, F.M., Anscher, M.S., Murase, T., Abbott, B.D., Iglehart, J.D. and Jirtle, R.L. (1995) Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor. Annals of Surgery, 222, 155-162. http://dx.http://dx.doi.org/10.1097/00000658-199508000-00007
|
[65]
|
Sheen-Chen, S.M., Chen, H.S., Sheen, C.W., Eng, H.L. and Chen, W.J. (2001) Serum levels of transforming growth factor beta1 in patients with breast cancer. Archives of Surgery, 136, 937-940. http://dx.http://dx.doi.org/10.1001/archsurg.136.8.937
|
[66]
|
Baselga, J., Rothenberg, M.L., Tabernero, J., Seoane, J., Daly, T., Cleverly, A., Berry, B., Rhoades, S.K., Ray, C.A., Fill, J., Farrington, D.L., Wallace, L. A., Yingling, J.M., Lahn, M., Arteaga, C. and Carducci, M. (2008) TGF-beta signalling-related markers in cancer patients with bone metastasis. Biomarkers, 13, 217-236. http://dx.http://dx.doi.org/10.1080/13547500701676019
|
[67]
|
Divella, R., Daniele, A., Savino, E., Palma, F., Bellizzi, A., Giotta, F., Simone, G., Lioce, M., Quaranta, M., Paradiso, A. and Mazzocca, A. (2013) Circulating levels of transforming growth factor-βeta (TGF-β) and chemokine (C-X-C motif) ligand-1 (CXCL1) as predictors of distant seeding of circulating tumor cells in patients with metastatic breast cancer. Anticancer Research, 33, 1491-1497.
|
[68]
|
Buck, M.B., Fritz, P., Dippon, J., Zugmaie, R.G. and Knabbe, C. (2004) Prognostic significance of transforming growth factor beta receptor II in estrogen receptornegative breast cancer patients. Clinical Cancer Research, 10, 491-498. http://dx.http://dx.doi.org/10.1158/1078-0432.CCR-0320-03
|
[69]
|
Richardsen, E., Uglehus, R.D., Johnsen, S.H. and Busund, L.T. (2012) Immunohistochemical expression of epithetlial and stromal immunomodulatory signalling molecules is a prognostic indicator in breast cancer. BMC Research Notes, 21, 110. http://dx.http://dx.doi.org/10.1186/1756-0500-5-110
|
[70]
|
de Kruijf, E.M., Dekker, T.J., Hawinkels, L.J., Putter, H., Smit, V.T., Kroep, J.R., Kuppen, P.J., van de Velde, C.J., ten Dijke, P., Tollenaar, R.A. and Mesker, W.E. (2013) The prognostic role of TGF-β signaling pathway in breast cancer patients. Ann Oncol, 24, 384-390. http://dx.http://dx.doi.org/10.1093/annonc/mds333
|
[71]
|
Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J. and Clarke, M.F. (2003) Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 100, 3983-3988. http://dx.http://dx.doi.org/10.1073/pnas.0530291100
|
[72]
|
Collins, A.T., Berry, P.A., Hyde, C., Stower, M.J. and Maitland, N.J. (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Research, 65, 10946-10951. http://dx.http://dx.doi.org/10.1158/0008-5472.CAN-05-2018
|
[73]
|
O’Brien, C.A., Pollett, A., Gallinger, S. and Dick, J.E. (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature, 445, 106-110. http://dx.http://dx.doi.org/10.1038/nature05372
|
[74]
|
Reya, T., Morrison, S.J., Clarke, M.F. and Weissman, I.L. (2001) Stem cells, cancer, and cancer stem cells. Nature, 414, 105-111. http://dx.http://dx.doi.org/10.1038/35102167
|
[75]
|
Ricci-Vitiani, L., Lombardi, D.G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C. and Maria, R. (2007) Identification and expansion of human colon-cancer-initiating cells. Nature, 445, 111-115. http://dx.http://dx.doi.org/10.1038/nature05384
|
[76]
|
Singh, S.K., Hawkins, C., Clarke, I.D., Squire, J.A., Bayani, J., Hide, T., Henkelman, R.M. and Cusimano, M.D., Dirks, P.B. (2004) Identification of human brain tumour initiating cells. Nature, 432, 396-401. http://dx.http://dx.doi.org/10.1038/nature03128
|
[77]
|
Hoogen, C., Horst, G., Cheung, H., Buijs, J.T., Lippitt, J.M., Guzman-Ramirez, N., Hamdy, F.C., Eaton, C.L., Thalmann, G.N., Cecchini, M.G., Pelger, R.C. and Pluijm, G. (2010) High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Research, 70, 5163-5173. http://dx.http://dx.doi.org/10.1158/0008-5472.CAN-09-3806
|
[78]
|
Clevers, H. (2011) The cancer stem cell: Premises, promises and challenges. Nature Medicine, 17, 313-319. http://dx.http://dx.doi.org/10.1038/nm.2304
|
[79]
|
Shipitsin, M., Campbell, L.L., Argani, P., Weremowicz, S., Bloushtain-Qimron, N., Yao, J., Nikolskaya, T., Serebryiskaya, T., Beroukhim, R., Hu, M., Halushka, M.K., Sukumar, S., Parker, L.M., Anderson, K.S., Harris, L.N., Garber, J.E., Richardson, A.L., Schnitt, S.J., Nikolsky, Y., Gelman, R.S. and Polyak, K. (2007) Molecular definition of breast tumor heterogeneity. Cancer Cell, 11(3), 259-273. http://dx.http://dx.doi.org/10.1016/j.ccr.2007.01.013
|
[80]
|
Mani, S.A., Guo, W., Liao, M.J., Eaton, E.N., Ayyanan, A., Zhou, A.Y., Brooks, M., Reinhard, F., Zhan,g C.C., Shipitsin, M., Campbell, L.L., Polyak, K., Brisken, C., Yang, J. and Weinberg, R.A. (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell, 133, 704-715. http://dx.http://dx.doi.org/10.1016/j.cell.2008.03.027
|
[81]
|
Scheel, C., Eaton, E.N., Li, S.H.-J., Chaffer, C.L., Reinhardt, F., Kah, K.-J., Bell, G., Guo, W., Rubin, J., Richardson, A.L., and Weinberg, R.A. (2011) Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell, 10, 926-940. http://dx.http://dx.doi.org/10.1016/j.cell.2011.04.029
|
[82]
|
Balko, J.M., Schwarz, L.J., Bhola, N.E., Kurupi, R., Owens, P., Miller, T.W., Gomez, H., Cook, R.S. and Arteaga, C.L. (2013) Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer. Cancer Research.
|
[83]
|
Kong, Y.Y., Yoshida, H., Sarosi, I., Tan, H.L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A.J., Van, G., Itie, A., Khoo, W., Wakeham, A., Dunstan, C.R., Lacey, D.L., Mak, T.W., Boyle, W.J. and Penninger, J. (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature, 397, 315-323. http://dx.http://dx.doi.org/10.1038/16852
|
[84]
|
Kong, Y.Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, J., Elliott, R., McCabe, S., Wong, T., Campagnuolo, G., Moran, E., Bogoch, E.R., Van, G., Nguyen, L.T., Ohashi, P.S., Lacey, D.L., Fish, E., Boyle. W.J and Penninger, J.M. (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature, 402, 304-309. http://dx.http://dx.doi.org/10.1038/46303
|
[85]
|
Franz-Odendaal, T.A., Hall, B.K. and Witten, P.E. (2006) Buried alive: How osteoblasts become osteocytes. Dev Dyn, 235, 176-190. http://dx.http://dx.doi.org/10.1002/dvdy.20603
|
[86]
|
Knothe, Tate, M.L., Adamson, J.R., Tami, A.E. and Bauer, T.W. (2004) The osteocyte. The International Journal of Biochemistry & Cell Biology, 36, 1-8. http://dx.http://dx.doi.org/10.1016/S1357-2725(03)00241-3
|
[87]
|
Iqbal, J. and Zaidi, M. (2005) Molecular regulation of mechanotransduction. Biochemical and Biophysical Research Communications, 328, 751-755. http://dx.http://dx.doi.org/10.1016/j.bbrc.2004.12.087
|
[88]
|
Robling, A.G., Niziolek, P.J., Baldridge, L.A., Condon, K.W., Allen, M.R., Alam, I., Mantila, SM., GluhakHeinrich, J., Bellido, T.M., Harris, S.E. and Turner, C.H. (2008) Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. The Journal of Biological Chemistry, 283, 5866-5875. http://dx.http://dx.doi.org/10.1074/jbc.M705092200
|
[89]
|
Hadjidakis, D.J. and Androulakis, I.I. (2006) Bone remodeling. Annals of the New York Academy of Sciences, 1092, 385-396. http://dx.http://dx.doi.org/10.1196/annals.1365.035
|
[90]
|
Seyedin, S.M., Thomas, T.C., Thompson, A.Y., Rosen, D.M. and Piez, K.A. (1985) Purification and characterization of two cartilage-inducing factors from bovine demineralized bone. Proceedings of the National Academy of Sciences of the United States of America, 82, 2267-2227. http://dx.http://dx.doi.org/10.1073/pnas.82.8.2267
|
[91]
|
Balooch, G., Balooch, M., Nalla, R.K., Schilling, S., Filvaroff, E.H., Marshall, G.W., Marshall, S.J., Ritchie, R.O., Derynck, R. and Alliston, T. (2005) TGF-beta regulates the mechanical properties and composition of bone matrix. Proceedings of the National Academy of Sciences of the United States of America, 102, 18813-18818. http://dx.http://dx.doi.org/10.1073/pnas.0507417102
|
[92]
|
Tang, Y., Wu, X., Lei, W., Pang, L., Wan, C., Shi, Z., Zhao, L., Nagy, T.R., Peng, X., Hu, J., Feng, X., Hul, W., Wan, M. and Cao, X. (2009) TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nature Medicine, 15, 757-765. http://dx.http://dx.doi.org/10.1038/nm.1979
|
[93]
|
Alliston, T., Choy, L., Ducy, P., Karsenty, G. and Derynck, R. (2001) TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. The EMBO Journal, 20, 2254-2272. http://dx.http://dx.doi.org/10.1093/emboj/20.9.2254
|
[94]
|
Janssens, K., Dijke, P., Janssens, S. and Hul, W. (2005) Transforming growth factor-beta1 to the bone. Endocrine Reviews, 26, 743-774. http://dx.http://dx.doi.org/10.1210/er.2004-0001
|
[95]
|
Iqbal, J., Sun, L. and Zaidi, M. (2009) Coupling bone degradation to formation. Nature Medicine, 15(7), 729-731. http://dx.http://dx.doi.org/10.1038/nm0709-729
|
[96]
|
Canalis, E. (2009) Growth factor control of bone mass. Journal of Cellular Biochemistry, 108, 769-777. http://dx.http://dx.doi.org/10.1002/jcb.22322
|
[97]
|
Maeda, S., Hayashi, M., Komiya, S., Imamura, T. and Miyazono, K. (2004) Endogenous TGF-beta signaling suppresses maturation of osteoblastic mesenchymal cells. The EMBO Journal, 23, 552-563. http://dx.http://dx.doi.org/10.1038/sj.emboj.7600067
|
[98]
|
Thirunavukkarasu, K., Miles, R.R., Halladay, D.L., Yang, X., Galvin, R.J., Chandrasekhar, S., Martin, T.J. and Onyia, J.E. (2001) Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. The Journal of Biological Chemistry, 276, 36241-36250. http://dx.http://dx.doi.org/10.1074/jbc.M104319200
|
[99]
|
Guo, L.J., Xie, H., Zhou, H.D., Luo, X.H., Peng, Y.Q. and Liao, E.Y. (2004) Stimulation of RANKL and inhibition of membrane-type matrix metalloproteinase-1 expression by parathyroid hormone in normal human osteoblasts. Endocrine Research, 30, 369-377. http://dx.http://dx.doi.org/10.1081/ERC-200033719
|
[100]
|
Oursler, M,J. (1994) Osteoclast synthesis and secretion and activation of latent transforming growth factor beta. Journal of Bone and Mineral Research, 9, 443-452. http://dx.http://dx.doi.org/10.1002/jbmr.5650090402
|
[101]
|
Rhodes, S.D., Wu, X., He, Y., Chen, S., Yang, H., Staser, K.W., Wang, J., Zhang, P., Jiang, C., Yokota, H., Dong, R., Peng, X., Yang, X., Murthy, S., Azhar, M., Mohammad, K.S., Xu, M., Guise, T.A. and Yang, F.C. (2013) Hyperactive transforming growth factor-β1 signaling potentiates skeletal defects in a neurofibromatosis type 1 mouse model. Journal of Bone and Mineral Research. http://dx.http://dx.doi.org/10.1002/jbmr.1992
|
[102]
|
Nistala, H., Lee-Arteaga, S., Smaldone, S., Siciliano, G. and Ramirez F. (2010) Extracellular microfibrils control osteoblast-supported osteoclastogenesis by restricting TGF{beta} stimulation of RANKLproduction. The Journal of biological chemistry, 285, 34126-34133. http://dx.http://dx.doi.org/10.1074/jbc.M110.125328
|
[103]
|
Nguyen, J., Tang, S.Y., Nguyen, D. and Alliston T. (2013) Load regulates bone formation and Sclerostin expression through a TGFβ-dependent mechanism. PLoS ONE, 8, e53813. http://dx.http://dx.doi.org/10.1371/journal.pone.0053813
|
[104]
|
Bednarz-Knoll, N., Alix-Panabières, C. and Pantel, K. (2011) Clinical relevance and biology of circulating tumor cells. Breast Cancer Research, 13, 228. http://dx.http://dx.doi.org/10.1186/bcr2940
|
[105]
|
Kang, Y., He, W., Tulley, S., Gupta, G.P., Serganova, I., Chen, C.R., Manova-Todorova, K., Blasberg, R., Gerald, W.L. and Massagué, J. (2005) Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proceedings of the National Academy of Sciences of the United States of America, 102, 13909-13914. http://dx.http://dx.doi.org/10.1073/pnas.0506517102
|
[106]
|
Javelaud, D., Mohammad, K.S., McKenna, C.R,, Fournier, P., Luciani, F., Niewolna, M., André, J., Delmas, V., Larue, L., Guise, T.A. and Mauviel, A. (2007) Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. Cancer Research, 67, 2317-2324. http://dx.http://dx.doi.org/10.1158/0008-5472.CAN-06-3950
|
[107]
|
Guise, T.A., Yin, J.J., Taylor, D., Kumagai, Y., Dallas, M., Boyce, B.F., Yoneda, T. and Mundy, G.R. (1996) Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. Journal of Clinical Investigation, 98, 1544-1549. http://dx.http://dx.doi.org/10.1172/JCI118947
|
[108]
|
Mundy, G.R. and Edwards, J.R. (2008) PTH-related peptide (PTHrP) in hypercalcemia. J Am Soc Nephrol, 19, 672-675. http://dx.http://dx.doi.org/10.1681/ASN.2007090981
|
[109]
|
Kohno, N., Kitazawa, S., Sakoda, Y., Kanbara, Y., Furuya, Y., Ohashi, O. and Kitazawa, R. (1994) Parathyroid hormone-related protein in breast cancer tissues: Relationship between primary and metastatic sites. Breast cancer, 1, 43-49. http://dx.http://dx.doi.org/10.1007/BF02967374
|
[110]
|
Henderson, M., Danks, J., Moseley, J., Slavin, J., Harris, T., McKinlay, M., Hopper, J. and Martin, T. (2001) Parathyroid hormone-related protein production by breast cancers, improved survival, and reduced bone metastases. Journal of the National Cancer Institute, 93, 234-237. http://dx.http://dx.doi.org/10.1093/jnci/93.3.234
|
[111]
|
Henderson, M.A., Danks, J.A., Slavin, J.L., Byrnes, G.B., Choong, P.F., Spillane, J.B., Hopper, J.L. and Martin, T.J. (2006) Parathyroid hormone-related protein localization in breast cancers predict improved prognosis. Cancer Research, 66, 2250-2256. http://dx.http://dx.doi.org/10.1158/0008-5472.CAN-05-2814
|
[112]
|
Kakonen, S.M., Selander, K.S., Chirgwin, J.M., Yin, J.J., Burns, S., Rankin, W.A., Grubbs, B.G., Dallas, M., Cui, Y. and Guise TA. (2002)Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. The Journal of Biological Chemistry, 277, 24571-24578. http://dx.http://dx.doi.org/10.1074/jbc.M202561200
|
[113]
|
Thomas, R.J., Guise, T.A., Yin, J.J., Elliott, J., Horwood, N.J., Martin, T.J. and Gillespie, M.T. (1999) Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology, 140, 4451-4458. http://dx.http://dx.doi.org/10.1210/en.140.10.4451
|
[114]
|
Brown, J.M. and Wilson, W.R. (2004) Exploiting tumour hypoxia in cancer treatment. Nature Reviews Cancer, 4, 437-447. http://dx.http://dx.doi.org/10.1038/nrc1367
|
[115]
|
Comerford, K.M., Wallace, T.J., Karhausen, J., Louis, N.A., Montalto, M.C. and Colgan S.P. (2002) Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Research, 15, 62, 3387-3394.
|
[116]
|
Wartenberg, M., Ling, F.C., Müschen, M., Klein, F., Acker, H., Gassmann, M., Petrat, K., Pütz, V., Hescheler, J. and Sauer, H. (2003) Regulation of the multidrug resistance transporter P-glycoprotein in multicellular tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species. The FASEB Journal, 17, 503-505.
|
[117]
|
Jubb, A.M., Buffa, F.M. and Harris, A.L. (2010) Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis. Journal of Cellular and Molecular Medicine, 14, 18-29. http://dx.http://dx.doi.org/10.1111/j.1582-4934.2009.00944.x
|
[118]
|
Hiraga, T., Kizaka-Kondoh, S., Hirota, K., Hiraoka, M. and Yoneda, T. (2007) Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Research, 67, 4157-4163. http://dx.http://dx.doi.org/10.1158/0008-5472.CAN-06-2355
|
[119]
|
McMahon, S., Charbonneau, M., Grandmont, S., Richard, D.E. and Dubois, C.M. (2006) Transforming growth factor beta1 induces hypoxia-inducible factor-1 stabilization through selective inhibition of PHD2 expression. The Journal of Biological Chemistry, 281, 24171-24181. http://dx.http://dx.doi.org/10.1074/jbc.M604507200
|
[120]
|
Dunn, L.K., Mohammad, K.S., Fournier, P.G, McKenna, C.R., Davis, H.W., Niewolna, M., Peng, X.H., Chirgwin, J.M. and Guise, T.A. (2009) Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS ONE, 4, e6896. http://dx.http://dx.doi.org/10.1371/journal.pone.0006896
|
[121]
|
Muraoka, R.S., Dumont, N., Ritter, C.A., Dugger, T.C., Brantley, D.M., Chen, J., Easterly, E., Roebuck, L.R., Ryan, S., Gotwals, P.J., Koteliansky, V. and Arteaga, C.L. (2002) Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. Journal of Clinical Investigation, 109, 1551-1559.
|
[122]
|
Muraoka-Cook, R.S., Kurokawa, H., Koh, Y., Forbes, J.T., Roebuck, L.R., Barcellos-Hoff, M.H., Moody, S.E., Chodosh, L.A. and Arteaga, C.L. (2004) Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors. Cancer Research, 64, 9002-9011. http://dx.http://dx.doi.org/10.1158/0008-5472.CAN-04-2111
|
[123]
|
Arteaga, C.L., Carty-Dugger, T., Moses, H.L., Hurd, S.D. and Pietenpol, J.A. (1993) Transforming growth factor beta 1 can induce estrogen-independent tumorigenicity of human breast cancer cells in athymic mice. Cell Growth & Differentiation, 4, 193-201.
|
[124]
|
Arteaga, C.L., Hurd, S.D., Winnie,r A.R., Johnson, M.D., Fendly, B.M. and Forbes, J.T. (1993) Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. Journal of Clinical Investigation, 92, 2569-2576. http://dx.http://dx.doi.org/10.1172/JCI116871
|
[125]
|
Nam, J.S., Suchar, A.M., Kang, M.J., Stuelten, C.H., Tang, B., Michalowska, A.M., Fisher, L.W., Fedarko, N.S,, Jain. A., Pinkas, J., Lonning, S. and Wakefield, L.M. (2006) Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer. Cancer Research, 66, 6327-6335. http://dx.http://dx.doi.org/10.1158/0008-5472.CAN-06-0068
|
[126]
|
Nam, J.S., Terabe, M., Kang, M.J., Chae, H., Voong, N., Yang, Y.A., Laurence, A., Michalowska, A., Mamura, M., Lonning, S., Berzofsky, J.A. and Wakefield, L.M. (2008) Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Research, 68, 3915-3923. http://dx.http://dx.doi.org/10.1158/0008-5472.CAN-08-0206
|
[127]
|
Nam, J.S., Terabe, M., Mamura, M., Kang, M.J., Chae, H., Stuelten, C., Kohn, E., Tang, B., Sabzevari, H., Anver, M.R., Lawrence, S., Danielpour, D., Lonning, S., Berzofsky, J.A. and Wakefield, L.M. (2008) An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Research, 68, 3835-3843. http://dx.http://dx.doi.org/10.1158/0008-5472.CAN-08-0215
|
[128]
|
Biswas, S., Nyman, J.S., Alvarez, J., Chakrabarti, A., Ayres, A., Sterling, J., Edwards, J., Rana, T., Johnson, R., Perrien, D.S., Lonning, S., Shyr, Y., Matrisian, L.M. and Mundy, G.R. (2011) Anti-Transforming Growth Factor ß Antibody Treatment Rescues Bone Loss and Prevents Breast Cancer Metastasis to Bone. PloS ONE, 6, e27090. http://dx.http://dx.doi.org/10.1371/journal.pone.0027090
|
[129]
|
Bandyopadhyay, A., Zhu, Y., Cibull, M.L., Bao, L., Chen, C. and Sun, L. (1999) A soluble transforming growth factor beta type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells. Cancer Research, 59, 5041-5046.
|
[130]
|
Bandyopadhyay, A., Lopez-Casillas. F., Malik, S.N., Montiel, J.L., Mendoza, V., Yang, J. and Sun, L.Z. (2002) Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft. Cancer Research, 62, 4690-4695.
|
[131]
|
Bennett, C.F. and Swayze, E.E. (2010) RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annual Review of Pharmacology and Toxicology, 50, 259-293. http://dx.http://dx.doi.org/10.1146/annurev.pharmtox.010909.105654
|
[132]
|
Crooke, S.T. (2004) Progress in antisense technology. Annual Review of Medicine, 55, 61-95. http://dx.http://dx.doi.org/10.1146/annurev.med.55.091902.104408
|
[133]
|
Inman, G.J., Nicolas, F.J., Callahan, J.F., Harling, J.D., Gaster, L.M., Reith, A.D., Laping, N.J. and Hill, C.S. (2002) SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Molecular Pharmacology, 62, 65-74. http://dx.http://dx.doi.org/10.1124/mol.62.1.65
|
[134]
|
Petersen, M., Thorikay, M., Deckers, M., Dinther, M., Grygielko, E.T., Gellibert, F., Gouville, A.C., Huet, S., Dijke, P. and Laping, N.J. (2008) Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis. Kidney International, 73, 705-715. http://dx.http://dx.doi.org/10.1038/sj.ki.5002717
|
[135]
|
Tojo, M., Hamashima, Y., Hanyu, A., Kajimoto, T., Saitoh, M., Miyazono, K., Node, M. and Imamura, T. (2005) The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta. Cancer Science, 96, 791-800. http://dx.http://dx.doi.org/10.1111/j.1349-7006.2005.00103.x
|
[136]
|
Byfield, S.D. and Roberts, A.B. (2004) Lateral signaling enhances TGF-beta response complexity. Trends in Cell Biology, 14, 107-111. http://dx.http://dx.doi.org/10.1016/j.tcb.2004.01.001
|
[137]
|
Fu, K., Corbley, M.J., Sun, L., Friedman, J.E., Shan, F., Papadatos, J.L., Costa, D., Lutterodt, F., Sweigard, H., Bowes, S., Choi, M., Boriack-Sjodin, P.A., Arduini, R.M., Sun, D., Newman, M.N., Zhang, X., Mead, J.N., Chuaqui, C.E., Cheung, H.K., Cornebise, M., Carter, M.B., Josiah, S., Singh, J., Lee, W.C., Gill, A. and Ling, L.E. (2008) SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model. Arteriosclerosis, Thrombosis, and Vascular Biology, 28, 665-671. http://dx.http://dx.doi.org/10.1161/ATVBAHA.107.158030
|
[138]
|
Ehata, S., Hanyu, A., Fujime, M., Katsuno, Y,, Fukunaga, E., Goto, K., Ishikawa, Y., Nomura, K., Yokoo, H., Shimizu, T., Ogata, E., Miyazono, K., Shimizu, K. and Imamura, T. (2007) Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Science, 98, 127-133. http://dx.http://dx.doi.org/10.1111/j.1349-7006.2006.00357.x
|
[139]
|
Mohammad, K.S., Chen, C.G., Balooch, G., Stebbins, E., McKenna, C.R., Davis, H., Niewolna, M., Peng, X.H., Nguyen, D.H., Ionova-Martin, S.S., Bracey, J.W., Hogue, W.R., Wong, D.H., Ritchie, R.O., Suva, L.J., Derynck, R., Guise, T.A. and Alliston T. (2009) Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS ONE, 4, e5275. http://dx.http://dx.doi.org/10.1371/journal.pone.0005275
|
[140]
|
Institute AAMCTCNC. (2009) Topical halofuginone hydrobromide in treating patients with HIV-related Kaposi’s sarcoma. National Cancer Institute. http://clinicaltrials.gov/ct2/show/NCT00064142,
|
[141]
|
Juárez, P., Mohammad, K.S., Yin, J.J., Fournier, P.G., McKenna, R.C., Davis, H.W., Peng, X.H., Niewolna, M., Javelaud, D., Chirgwin, J.M., Mauviel, A. and Guise. T.A. (2012) Halofuginone inhibits the establishment and progression of melanoma bone metastases. Cancer Research, 1, 6247-6256. http://dx.http://dx.doi.org/10.1158/0008-5472.CAN-12-1444
|
[142]
|
Gadir, N., Jackson, D.N., Lee, E. and Foster, D.A. (2008) Defective TGF-beta signaling sensitizes human cancer cells to rapamycin. Oncogene, 27, 1055-1062. http://dx.http://dx.doi.org/10.1038/sj.onc.1210721
|
[143]
|
Filyak, Y., Filyak, O. and Stoika, R. (2007) Transforming growth factor beta-1 enhances cytotoxic effect of doxorubicin in human lung adenocarcinoma cells of A549 line. Cell Biology International, 31, 851-855. http://dx.http://dx.doi.org/10.1016/j.cellbi.2007.02.008
|
[144]
|
Taniguchi, Y., Kawano, K., Minowa, T., Sugino, T., Shimojo, Y. and Maitani, Y. (2010) Enhanced antitumor efficacy of folate-linked liposomal doxorubicin with TGFbeta type I receptor inhibitor. Cancer Science, 101, 2207-2213. http://dx.http://dx.doi.org/10.1111/j.1349-7006.2010.01646.x
|
[145]
|
Mohammad, K.S., Stebbins, E.G., Kingsley, L., Fournier, P.G.J., Niewolna, M., McKenna, C.R., Peng, X., Higgins, L., Wong, D. and Guise, T.A. (2008) Combined transforming growth factor b receptor I kinase inhibitor and biphosphonates are additve to reduce breast cancer bone metastases. Journal of Bone and Mineral Research, 23, F275.
|
[146]
|
Hengst, V., Oussoren, C., Kissel, T. and Storm, G. (2007) Bone targeting potential of bisphosphonate-targeted liposomes. Preparation, characterization and hydroxyapatite binding in vitro. International Journal of Pharmaceutics, 331, 224-227. http://dx.http://dx.doi.org/10.1016/j.ijpharm.2006.11.024%%
|